01—Abstract
Summary
Summary of the 8-K filed February 13, 2026. Cited figures are marked; the original filing is the authoritative source.
On February 13, 2026, Cencora, Inc. (NYSE: COR) closed a $3.0 billiona underwritten senior unsecured notes offering across five tranches: $500M 3.950% notes due 2029, $500M 4.250% notes due 2030, $500M 4.600% notes due 2033, $1.0B 4.900% notes due 2036, and $500M 5.650% notes due 2056.
The notes rank equally with the company's existing unsecured senior debt but are structurally subordinated to all liabilities of its subsidiaries, including trade payables. The indentures contain customary covenants limiting liens, sale-leaseback transactions, and mergers or sales of substantially all assets, along with standard events of default. The proceeds are earmarked primarily to repay borrowings under a 364-day term credit agreement dated January 12, 2026, which financed part of the acquisition of OneOncology.
Refinancing that bridge facility with long-term fixed-rate debt extends the company's maturity profile and replaces short-term acquisition financing, with any remaining proceeds going to general corporate purposes. The 8-K itself does not disclose the total interest cost, the net proceeds after underwriting discounts, or pro forma leverage, so investors should consult the prospectus supplement and subsequent 10-Q for those figures. For investors, the filing signals that Cencora has accessed the investment-grade bond market at a substantial scale to fund its OneOncology acquisition.
Weighted coupon costs are meaningful across the curve, with the 2056 tranche carrying a 5.650%b rate. Because the filing is largely a financing disclosure, the key ongoing considerations are the incremental interest expense this debt adds, the resulting leverage, and whether the OneOncology acquisition delivers the anticipated returns.
02—Key points
Key Highlights
- Closed a $3.0 billion senior unsecured notes offering in five tranches maturing 2029 through 2056, with coupons from 3.950% to 5.650%.
- Largest tranche is $1.0 billion of 4.900% notes due 2036; the 2029, 2030, 2033 and 2056 tranches are $500 million each.
- Proceeds are primarily earmarked to repay the 364-day term credit agreement dated January 12, 2026 that financed part of the OneOncology acquisition.
- Notes are unsecured and rank equally with existing unsecured senior debt, but are structurally subordinated to all subsidiary liabilities, including trade payables.
- Indentures include customary covenants restricting liens, sale-leaseback transactions, and mergers or sales of substantially all assets, with standard events of default.
- Issued under the shelf registration statement filed November 26, 2024, in an underwritten public offering led by Citigroup, J.P. Morgan, BofA Securities and Wells Fargo Securities.
- The 8-K does not disclose net proceeds, the all-in interest cost, or pro forma leverage; these are expected in the prospectus supplement and future filings.
03—Questions
Frequently Asked Questions
How much debt did Cencora raise and what are the maturities?
Cencora raised $3.0 billion across five series of senior notes: $500M due February 13, 2029 (3.950%), $500M due November 15, 2030 (4.250%), $500M due February 13, 2033 (4.600%), $1.0B due February 13, 2036 (4.900%), and $500M due February 13, 2056 (5.650%).
Why is Cencora issuing this debt?
The company plans to use the net proceeds to repay amounts outstanding under a 364-day term credit agreement dated January 12, 2026, which helped fund its acquisition of OneOncology. Any remaining proceeds will go to general corporate purposes.
How does this debt rank relative to other obligations?
The notes are unsecured and rank equally in right of payment with all existing and future unsecured, unsubordinated company debt. They are structurally subordinated to all liabilities of the subsidiaries, including trade payables, meaning creditors of those subsidiaries are paid before noteholders from subsidiary assets.
Are there restrictions on the company under these notes?
Yes. Subject to exceptions, the indentures limit Cencora and its restricted subsidiaries from creating liens and entering sale-leaseback transactions, and limit mergers or sales of all or substantially all assets. Events of default include nonpayment, covenant breaches, cross-defaults on other debt, unpaid final judgments, and bankruptcy-type proceedings.
Can Cencora redeem the notes early?
Yes. Each series can be redeemed before its par call date at a make-whole price, which cannot be less than principal. The 2029 notes become callable at par on January 13, 2029, the 2030 notes on October 15, 2030, the 2033 notes on December 13, 2032, the 2036 notes on November 13, 2035, and the 2056 notes on August 13, 2055.
04—Continue